The constitutive activation of STAT5 signalling in cancer can be abrogated by STAT5 inhibitors (Table 2) or tyrosine kinase inhibitors (TKIs) (Table 3) that target the upstream signalling molecules, such as JAK, Flt3 and Bcr-Abl. This evidence concerns the gene STAT5B and cancer.